In this video, Jeff Yu, MD, MS, emphasized the importance of chronic hand eczema awareness and highlighted a study on the causes and treatments of the disease, presented at the Revolutionizing Atopic ...

Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

A genetically-induced skin disease, commonest in boys and women shall be the centrepiece campaign of dermatologists in the ...

When somebody's coming in that has a known diagnosis of atopic dermatitis or eczema and things are really revved up still, if ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

Any physical activity can be beneficial for eczema, as long as you’re choosing the right clothing and practicing good habits ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

According to a recent meta-analysis published in eClinicalMedicine, antibiotic use during pregnancy or in early childhood ...